Jaguar Health, Inc.
crofelemer
rare intestinal failure diseases
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for crofelemer in rare intestinal failure diseases are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“an ongoing investigator-initiated proof-of-concept trial in pediatric patients with intestinal failure due to MVID and short bowel syndrome (SBS-IF), crofelemer demonstrated a reduction of parenteral support (nutritional support combined wi”